Summary
Regeneron Pharmaceuticals, Inc. (REGN) reported strong top-line growth in the first quarter of 2014, with total revenues increasing by 42% year-over-year to $625.7 million. This growth was primarily driven by a 14% increase in Net Product Sales, largely due to higher volumes of EYLEA in the U.S., and a significant surge in Collaboration Revenue. Collaboration Revenue more than doubled to $255.8 million, propelled by substantial increases in revenue from Sanofi and Bayer HealthCare, reflecting strong performance in EYLEA sales outside the U.S. and key milestone payments. Despite this revenue expansion, net income decreased by 34% to $65.4 million, or $0.58 per diluted share, compared to $98.9 million, or $0.90 per diluted share in the prior year. This decrease was primarily due to a significant increase in Research and Development expenses, which rose 59% year-over-year to $287.4 million, and a substantially higher effective tax rate of 62.7% in the current quarter compared to 30.3% in the prior year quarter. The company continues to invest heavily in its pipeline, with ongoing clinical trials for key drug candidates like alirocumab and dupilumab showing progress. Significant milestones were achieved in the quarter, including the submission of a supplemental BLA for EYLEA in DME and positive Phase 3 results for EYLEA in BRVO. The company also received significant collaboration revenue from Bayer HealthCare related to EYLEA milestones and the PDGFR-beta antibody agreement. While the company's overall financial position remains strong with substantial cash and marketable securities, the increased R&D spending and higher tax rate present headwinds to near-term profitability, though the robust revenue growth and pipeline progress are positive indicators for long-term investor value.
Financial Highlights
46 data points| Revenue | $625.74M |
| Cost of Revenue | $27.47M |
| Gross Profit | $598.27M |
| R&D Expenses | $287.38M |
| SG&A Expenses | $103.23M |
| Operating Expenses | $434.18M |
| Operating Income | $191.56M |
| Interest Expense | $11.61M |
| Net Income | $68.31M |
| EPS (Basic) | $0.69 |
| EPS (Diluted) | $0.61 |
| Shares Outstanding (Basic) | 98.71M |
| Shares Outstanding (Diluted) | 112.15M |
Key Highlights
- 1Total revenues surged 42% year-over-year to $625.7 million, driven by robust EYLEA sales and strong collaboration revenue.
- 2Net Product Sales increased 14% to $362.4 million, primarily due to higher EYLEA volumes.
- 3Collaboration Revenue more than doubled, reaching $255.8 million, boosted by Sanofi and Bayer HealthCare partnerships, including significant milestone payments.
- 4Net income decreased by 34% to $65.4 million, impacted by increased R&D investments and a higher effective tax rate.
- 5Research and Development expenses rose significantly by 59% to $287.4 million, reflecting continued pipeline investment.
- 6Positive clinical trial updates for EYLEA in DME and BRVO, along with progress in antibody-based programs like alirocumab and dupilumab, underscore pipeline strength.
- 7The company maintains a strong liquidity position with $1.18 billion in cash, cash equivalents, and marketable securities as of March 31, 2014.